Lyme disease Market: Epidemiology, Therapies, Companies, DelveInsight | Pfizer, ModernaTX, Inc., Tarsus Pharmaceuticals, Inc., Valneva, Cortene, Blue Lake Biotechnology, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics

Lyme disease therapies, such as VLA15, mRNA-1975, TP-05, mRNA-1982, and others, are expected to boost the Lyme disease Market in the upcoming years.

DelveInsight has launched a new report on "Lyme disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Lyme disease, historical and forecasted epidemiology as well as the Lyme disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Lyme disease market report @ https://www.delveinsight.com/report-store/lyme-disease-ld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Lyme disease Market Report:

DelveInsight's research indicates that the Lyme disease market across the seven major markets (7MM) is projected to experience strong compound annual growth by 2032.
In 2022, the United States recorded the highest number of Lyme disease cases among these regions.
On a global scale, major pharmaceutical companies, such as Pfizer, ModernaTX, Inc., Tarsus Pharmaceuticals, Inc., Valneva, Cortene, Blue Lake Biotechnology, Inovio Pharmaceuticals, Aegis Life, and Abzyme Therapeutics, are actively working on innovative treatments for Lyme disease that may enter the market in the near future.
Key therapies currently in development include VLA15, mRNA-1975, TP-05, mRNA-1982, among others.
On September 4, 2024, the FDA granted clearance to the iDartTM Lyme IgG ImmunoBlot Kit developed by ID-FISH Technology, Inc. This test is designed to detect IgG antibodies against Borrelia species responsible for Lyme disease. Notably, it features 31 antigen bands, including OspA (P31) and OspB (P34), enhancing its sensitivity and specificity compared to existing immunoblot tests.
In 2022, the FDA released guidance to assist in the development of drugs targeting early Lyme disease, particularly cases presenting with erythema migrans (EM), a characteristic skin rash. This guidance outlines the FDA's recommendations for clinical trial designs, endpoints, and other considerations to support the approval of new treatments aimed at early-stage Lyme disease.
On July 29, 2019, the U.S. Food and Drug Administration (FDA) cleared four previously approved tests with new indications to aid in the diagnosis of Lyme disease. These tests introduced a modified two-tier testing approach that utilizes enzyme immunoassays (EIA) both as the initial and confirmatory tests, replacing the traditional method that required a Western Blot as the second step. This streamlined method aims to facilitate earlier and more reliable detection of Lyme disease, potentially leading to improved patient outcomes.

Lyme disease Overview

Lyme disease, or Lyme borreliosis, is a bacterial infection primarily caused by Borrelia burgdorferi, with Borrelia mayonii responsible for some cases. It is transmitted to humans through the bite of infected black-legged ticks. Typical symptoms include fever, fatigue, headache, and a characteristic skin rash known as erythema migrans. If not treated, the infection can progress and impact the joints, heart, and nervous system. The most common early sign is the erythema migrans rash, which usually forms at the site of the tick bite and expands outward as a red patch. Diagnosis is often based on a history of tick exposure or residence in endemic areas. Testing is most reliable several weeks after infection, once antibodies are present, and is not recommended during the early localized stage of the disease.

Lyme disease Market Outlook

The treatment of Lyme disease depends on the stage of the illness, with antibiotic therapy tailored to the specific clinical presentation. Recent guidelines emphasize selecting appropriate antibiotics based on the disease stage to improve treatment outcomes.

Antimicrobial therapy is generally effective, especially when started early, such as upon detection of the erythema migrans rash. In later stages, longer treatment may be necessary, and effectiveness may decrease. For early or early disseminated Lyme disease without neurological symptoms, a 14-21 day course of doxycycline or amoxicillin is typically recommended.

However, late-stage Lyme disease with arthritis or neurological complications may be less responsive to standard antibiotics. Research by Wu et al. found that non-replicating *Borrelia burgdorferi* (Bb) forms are vulnerable to cell wall synthesis inhibitors, with vancomycin showing strong in vitro activity. Further studies by Feng et al. identified FDA-approved drugs, including a combination of daptomycin, cefoperazone (or cefuroxime), and doxycycline, as particularly effective in eliminating persistent Bb forms both in vitro and in a mouse model.

Discover how the Lyme disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/lyme-disease-ld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Lyme disease Therapies and Key Companies
VLA15: Pfizer
mRNA-1975: ModernaTX, Inc.
TP-05: Tarsus Pharmaceuticals, Inc.
mRNA-1982: ModernaTX, Inc.

Scope of the Lyme disease Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Lyme disease Companies: Pfizer, ModernaTX, Inc., Tarsus Pharmaceuticals, Inc., Valneva, Cortene, Blue Lake Biotechnology, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics, and others
Key Lyme disease Therapies: VLA15, mRNA-1975, TP-05, mRNA-1982, and others
Lyme disease Therapeutic Assessment: Lyme disease current marketed and Lyme disease emerging therapies
Lyme disease Market Dynamics: Lyme disease market drivers and Lyme disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Lyme disease Unmet Needs, KOL's views, Analyst's views, Lyme disease Market Access and Reimbursement

To know what's more in our Lyme disease report, visit https://www.delveinsight.com/report-store/lyme-disease-ld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Lyme disease Market Report:
Lyme disease market report covers a descriptive overview and comprehensive insight of the Lyme disease Epidemiology and Lyme disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Lyme disease market report provides insights into the current and emerging therapies.
The Lyme disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Lyme disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Lyme disease market.

Got queries? Click here to know more about the Lyme disease market Landscape https://www.delveinsight.com/sample-request/lyme-disease-ld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Lyme disease Patient Share (%) Overview at a Glance
5. Lyme disease Market Overview at a Glance
6. Lyme disease Disease Background and Overview
7. Lyme disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Lyme disease
9. Lyme disease Current Treatment and Medical Practices
10. Unmet Needs
11. Lyme disease Emerging Therapies
12. Lyme disease Market Outlook
13. Country-Wise Lyme disease Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Lyme disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Lyme disease Market Outlook 2034 https://www.delveinsight.com/report-store/lyme-disease-ld-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Lyme disease Pipeline Insights, DelveInsight

"Lyme disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Lyme disease market. A detailed picture of the Lyme disease pipeline landscape is provided, which includes the disease overview and Lyme disease treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.